The Daiichi Sankyo CDK8 kinase inhibitor, DS96432529, is intended to be a bone anabolic agent. The molecule shows preclinical efficacy and synergy with alendronate or parathyroid hormone. The discovery program was initiated well before the likely target (CDK8) was identified and provides an interesting retrospective case study for [...]
< 1 minute read
Dec. 20, 2021
DS96432529: a CDK8 Kinase Inhibitor Intended as a Bone Anabolic Agent
DS96432529
oral CDK8 kinase inhibitor effective in ovariectomized rat model CDK8 identified as MoA after screen Bioorganic & Medicinal Chemistry Letters Daiichi Sankyo Co. Ltd.